Editorial
Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

https://doi.org/10.1016/j.jtho.2018.12.011Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

Disclosure: Dr. Champiat has received honoraria from Amgen, AstraZeneca, BMS, Janssen, MSD, Novartis, and Roche. As part of the Drug Development Department of Institut Gustave Roussy, Dr. Champiat is subinvestigator of clinical trials for AbbVie, Agios Pharmaceuticals, Amgen, Argen-X BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer Healthcare AG, BBB Technologies B.V., Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Eli Lilly and Company, Exelixis, Forma, Gamamabs, Genentech, Inc., GlaxoSmithKline, H3 Biomedicine, Inc., Hoffmann La Roche AG, Innate Pharma, Iris Servier, Janssen Cilag, Kyowa Kirin Pharmaceutical Development, Inc., Loxo Oncology, Lytix Biopharma AS, Medimmune, Menarini Ricerche, Merck Sharp and Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology NV, Oncoethix, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Roche, Sanofi Aventis, Taiho Pharma, Tesaro, Inc., and Xencor. Also as part of the Drug Development Department of Institut Gustave Roussy, Dr. Champiat has received research grants from AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi and nonfinancial support (drugs supplied) from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson and Johnson, Eli Lilly and Company, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. Dr. Besse reports performing research at Institut Gustave Roussy that was sponsored by AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly and Company, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, PharmaMar SA, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work. The remaining authors declare no conflict of interest.